Inflammation Stocks List Ranked for 2024 | NYSE,

Symbol	Grade	Name	% Change
ALRN	F	Aileron Therapeutics, Inc.	-4.26
EYPT	F	EyePoint Pharmaceuticals, Inc.	7.19
EQ	F	Equillium, Inc.	-1.25
ATNF	F	180 Life Sciences Corp.	-1.32
CTXR	F	Citius Pharmaceuticals, Inc.	-18.96
GSK	F	GlaxoSmithKline PLC	0.00
ICU	F	SeaStar Medical Holding Corporation	-6.82
MTNB	F	Matinas Biopharma Holdings, Inc.	6.21
REGN	F	Regeneron Pharmaceuticals, Inc.	-0.87
GLTO	F	Galecto, Inc.	-3.85

Symbol	Grade	Name	Weight
BBH	D	Market Vectors Biotech ETF	18.12
IHI	A	iShares U.S. Medical Devices ETF	16.82
IBBQ	F	Invesco Nasdaq Biotechnology ETF	14.91
CANC	F	Tema Oncology ETF	13.78
IBB	F	iShares Nasdaq Biotechnology Index Fund	12.23

Compare ETFs

Compare BBH to IBB Compare BBH to IHI Compare CANC to IBB

Date	Stock	Title
Nov 22	CTXR	Citius Pharmaceuticals announces 1-for-25 reverse stock split
Nov 22	CTXR	Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
Nov 22	ICU	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
Nov 20	GSK	CDC warns of an imminent spike in COVID, flu cases
Nov 19	REGN	Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
Nov 19	REGN	Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
Nov 19	REGN	Regeneron: The Biotech Stock To Buy Now
Nov 19	GSK	GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
Nov 19	GSK	GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
Nov 19	GSK	GSK reports positive Phase 3 results for linerixibat in PBC itching
Nov 19	REGN	Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Nov 18	CTXR	Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
Nov 18	REGN	FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 18	GSK	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Inflammation: Inflammation is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and initiate tissue repair.